
In the Claims:

Claims 1-12 (Canceled)

13. (Currently Amended) A compound of the structural formula I:



Formula I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof:

wherein,

R represents hydrogen, or C_{1-6} alkyl;

X represents $-(CHR_7)_pCO-$;

Y represents $-CO(CH_2)_n-$,;

Q represents N;

R_w represents H, C_{1-6} alkyl, $-C(O)C_{1-6}$ alkyl, $-C(O)OC_{1-6}$ alkyl, $-SO_2N(R)_2$, $-SO_2C_{1-6}$ alkyl, $-SO_2C_{6-10}$ aryl, NO_2, CN or $-CON(R)_2$;

R_2 represents hydrogen, C_{1-10} alkyl, $-(CH_2)_nC_{3-8}$ cycloalkyl, said alkyl, optionally substituted with 1-3 groups selected from R^a;

R_3 represents hydrogen, C_{1-10} alkyl, $-(CH_2)_nC_{3-8}$ cycloalkyl, said alkyl, optionally substituted with 1-3 groups of R^a;

~~or, when Q is N, R_2 and R_3 taken together with the intervening N atom form a 4-10 membered heterocyclic carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from R^a;~~

R_4 and R_5 independently represent hydrogen, C_{1-6} alkoxy, OH, C_{1-6} alkyl, SO_qC_{1-6} alkyl, COC_{1-6} alkyl, COOR, SO_3H, $-O(CH_2)_nN(R)_2$, $-O(CH_2)_nCO_2R$, CF_3, OCF_3, $-N(R)_2$, nitro, cyano, C_{1-6} alkylamino, or halogen; ~~and~~

R_6 represents hydrogen, C_{1-10} alkyl, $-(CH_2)_nC_{6-10}$ aryl, NR_cR_d, $-NR(CH_2)_nC_{6-10}$ aryl, $-N((CH_2)_nC_{6-10}$ aryl$)_2$, $-(CH_2)_nC_{3-10}$ heterocyclyl, $-NR(CH_2)_nC_{3-10}$ heterocyclyl, $-N((CH_2)_nC_{3-10}$ heterocyclyl$)_2$, $(C_{6-10}$ aryl$)O-$, $-(CH_2)_nC_{3-8}$ cycloalkyl, -COOR, $-C(O)CO_2R$, said aryl, heterocyclyl and alkyl optionally substituted with 1-3 groups selected from R^a, wherein the R^a(s) can be attached to any carbon atom or heteroatom selected from N and S;

R_c and R_d independently represent H, C1-6 alkyl, C_{2-6} alkenyl, C_{1-6} alkylSR, $-(CH_2)_nO(CH_2)_mOR$, $-(CH_2)_nC_{1-6}$ alkoxy, $-(CH_2)_nC_{3-8}$ cycloalkyl;

or R_c and R_d taken together with the intervening N atom form a 4-10 membered heterocyclic carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from R^a;

R_7 represents hydrogen, C_{1-6} alkyl, $-(CH_2)_nCOOR$ or $-(CH_2)_nN(R)_2$,

R_8 represents $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_n$ 3-10 heterocyclyl, C_{1-6} alkoxy – or $(CH_2)_nC_{6-10}$ aryl said heterocyclyl, or aryl optionally substituted with 1-3 groups selected from R^a;

R^a represents F, Cl, Br, I, CF_3, $N(R)_2$, NO_2, CN, -O-, $-COR_8$, $-CONHR_8$, $-CON(R_8)_2$, $-O(CH_2)_nCOOR$, $-NH(CH_2)_nOR$, -COOR, $-OCF_3$, CF_2CH_2OR, -NHCOR, $-SO_2R$, $-SO_2NR_2$, -SR, $(C_1$-C_6 alkyl$)O-$, $-(CH_2)_nO(CH_2)_mOR$, $-O(CH_2)_nO(CH_2)_mOR$, $-(CH_2)_nC_{1-6}$ alkoxy, (aryl)O-, $-(CH_2)_nOH$, $(C_1$-C_6 alkyl$)S(O)_m-$, H_2N-C(NH)-, $(C_1$-C_6 alkyl$)C(O)-$, $(C_1$-C_6 alkyl$)OC(O)NH-$, $-(C_1$-C_6 alkyl$)NR_w(CH_2)_nC_{3-10}$ heterocyclyl-R_w, $-(C_1$-C_6 alkyl$)O(CH_2)_nC_{3-10}$ heterocyclyl-R_w, $-(C_1$-C_6 alkyl$)S(CH_2)_nC_{3-10}$ heterocyclyl-R_w, $-(C_1$-C_6 alkyl$)$-C_{3-10} heterocyclyl-R_w, $-(CH_2)_n$-Z^1-$C(=Z^2)N(R)_2$, $-(C_{2-6}$ alkenyl$)NR_w(CH_2)_nC_{3-10}$ heterocyclyl-R_w, $-(C_{2-6}$ alkenyl$)O(CH_2)_nC_{3-10}$ heterocyclyl-R_w, $-(C_{2-6}$ alkenyl$)S(CH_2)_nC_{3-10}$ heterocyclyl-R_w, $-(C_{2-6}$ alkenyl$)$-C_{3-10}

heterocyclyl-R_w, -(C_{2-6} alkenyl)-Z^1-C(=Z^2)N(R)$_2$, -$(CH_2)_nSO_2R$, -$(CH_2)_nSO_3H$, -C_{3-10}cycloalkyl, C_{6-10} aryl, C_{3-10} heterocyclyl, C_{2-6} alkenyl, and C_1-C_{10} alkyl, said alkyl, alkenyl, alkoxy, heterocyclyl and aryl optionally substituted with 1-3 groups selected from C_1-C_6 alkyl, halogen, CN, NO_2, -$(CH_2)_nOH$, CON(R)$_2$ and COOR;

Z^1 and Z^2 independently represents NR_w, O, CH_2, or S;

m is 0-3;

n is 0-3;


p is 0-3 and







q is 0-2.







14. (Currently Amended) A compound according to Claim 13 wherein R_6 is $(CH_2)_nC_{6-10}$ aryl, $(CH_2)_nC_{3-10}$ heterocyclyl, NR_cR_d or $(CH_2)_nC_{3-8}$ cycloalkyl, said aryl, heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a, and R_4 and R_5 independently represent hydrogen, C_{1-6} alkoxy, OH, C_{1-6} alkyl.









15. (Currently Amended) A compound of Table 1 through 4 which is:

Table 1



R1	R2	R3
H	Phenyl	
H	Phenyl	
H	Phenyl	
H	Phenyl	
H	Phenyl	
H	Phenyl	
H	Phenyl	
OMe	Phenyl	

R1	R2	R3
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	

OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	

















OMe	Isopropyl	

Table 2



R2	R3
	
	
	
	
	
	
	
	
	















R2	R3
	
	
	
	
	
	
	

Table 3








Table 4





or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

16. Canceled.

17. Canceled.

18. Canceled.

19. Canceled.

20. (Original) A composition comprising a compound of formula I of Claim 13 and a pharmaceutically acceptable carrier.

21. (Original). The composition according to Claim 20 wherein the compound of formula I is applied as a topical formulation, said topical formulation administered as a solution or suspension and optionally containing xanthan gum or gellan gum.

22. (Original) A composition according to Claim 20 wherein an active ingredient belonging to the group consisting of: beta-adrenergic blocking agent, parasympatho-mimetic agent, sympathomimetic agent, carbonic anhydrase inhibitor, EP4 agonist, a prostaglandin or derivative thereof, hypotensive lipid, neuroprotectant, and/or 5-HT2 receptor agonist is optionally added.

23. (Currently Amended) A composition according to Claim 22 wherein the beta-adrenergic blocking agent is timolol, betaxolol, levobetaxolol, carteolol, or levobunolol; the parasympathomimetic agent is pilocarpine; the sympathomimetic agent is epinephrine, brimonidine, iopidine, clonidine, or para-aminoclonidine, the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, metazolamide or brinzolamide; the prostaglandin is latanoprost, travaprost, unoprostone~~, rescula or~~ (Rescula®), ~~or S1033~~, the hypotensive lipid is lumigan, the neuroprotectant is eliprodil, R-eliprodil or memantine; and the 5-HT2 receptor agonist is 1-(2-aminopropyl)-3-methyl-1H-imdazol-6-ol fumarate or 2-(3-chloro-6-methoxy-indazol-1-yl)-1-methyl-ethylamine.